CXCR1 and cancer: We therefore tested an alternative Ccr7 inhibition approach using navarixin, a small molecule negative allosteric modulator of Ccr7, Cxcr1, and Cxcr2 that has been studied in clinical trials for airway disease and cancer indications (Jaeger et al., 2019; Rennard et al., 2015; Armstrong et al., 2024).